Now Available on Cell Therapy News – Cell Therapy Markets by TriMark Publications
Click here for more information
Glaxo, Astra, Roche Back Stem Cells for Drug Tests
Three of Europe’s top drugmakers have backed a new public-private scheme to use stem cells for safety testing of experimental medicines, signaling “big pharma’s” growing interest in the controversial field.
Axcan Licenses Rights to Cx401, an Innovative Biological Product in Development for the Treatment of Perianal Fistulas, a Significant Unmet Medical Need
Axcan Pharma Inc. has announced it has entered into an exclusive license and development agreement with Cellerix SL of Spain, for the North American rights to Cx401, an innovative biological product in development for the treatment of perianal fistulas.
Alnylam Grants GeneDesign License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market
This patent family, owned exclusively by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells.
South East Asia’s Largest Cord Blood Bank Opens
Indonesia has opened its first cord blood bank – the biggest in South-east Asia to date.
WARF Submits Technical Changes to Stem Cell Patents
The amendments attempt to clarify claim language to make the language consistent among the three stem cell patents under re-examination.
Venture Capital Firm Eyes Big Payoff In Life Sciences
Venture capital is flooding into life sciences. During the first half of 2007 VCs invested $4.8 billion in biotechnology and medical devices, says a report by PricewaterhouseCoopers and the National Venture Capital Association.
Private Funds Keep Stem Cell Research Viable in Seattle
In an attempt to get around the restrictions on federal money and avoid a potential siphoning of talent, scientists and some business leaders are working to keep Seattle in the game by encouraging privately funded stem cell research, an area in which we already are far behind California and some other states.
NIH Awards $310,000 Grant to Arteriocyte and Cleveland Clinic for Eye Disease Research
Arteriocyte, Inc. has today the successful award of a $310,000 National Institute of Health grant to evaluate its cellular therapy product (ACY001) as a potential treatment for diabetic retinopathies in collaboration with researchers at Cleveland Clinic.
Cardiac Stem Cell Therapy Company, Cardio3 BioSciences, Appoints Former New Jersey Medical School Assistant Professor, Dr. Vinciane Gaussin, as its Chief Scientific Officer
“The addition of Dr. Gaussin to our management team represents an important milestone in our mission to position Cardio3 BioSciences as a global leader in the field of regenerative therapies for heart failure,” said Christian Homsy, M.D., CEO of Cardio3 BioSciences.
WaferGen Announces Key Additions to Senior Management Team
WaferGen Biosystems, has announced the appointments of Sharat Singh, Ph.D., as senior vice president of research and development and Christopher S. Maki as vice president of worldwide sales.